Despite the growing interest in developing medicines based on psychedelic compounds, big pharma has seemed a bit wary of getting involved, leaving the task to small start-ups.
Psychedelic medicines developer Mydecine has joined forces with digital health company Maya to make digital tools that will be used alongside its drug candidates for mental health and addic
Compass Pathways has reported that its drug for treatment-resistant depression (TRD) based on magic mushroom ingredient psilocybin was effective in a phase 2b trial, although shares in the
Psychedelic medicines specialist Beckley Psytech has enticed a senior figure in Janssen's neuroscience division to take on the role of its chief medical officer as it ushers its first drugs
The first patient has received a low dose of Beckley Psytech's psychedelic medicine psilocybin in a clinical trial for short-lasting unilateral neuralgiform headache attacks (SUNHA), a rare
UK psychedelic medicine specialist Beckley Psytech has raised an impressive £58 million (around $80 million) in an oversubscribed second-round financing that will help fund clinical develop